Huadong Medicine Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Huadong Pharmaceutical Co., Ltd. (securities code: 000963) was founded in 1993 and headquartered in Hangzhou, Zhejiang. It was listed on the Shenzhen Stock Exchange in December 1999. After more than 20 years of development, the company's business covers the entire pharmaceutical industry chain, with the pharmaceutical industry as the leading force. At the same time, it expands its pharmaceutical business, medical aesthetics industry, and industrial microbiology business, and has developed into a large comprehensive pharmaceutical listed company that integrates pharmaceutical research and development, production, and distribution. The pharmaceutical industry of the company is deeply engaged in the research and development, production, and sales of specialized, chronic disease drugs, and special medication fields. It has formed a complete pharmaceutical production and quality research system, and formed a core product pipeline mainly in the fields of chronic kidney disease, transplant immunity, endocrine, digestive system, etc. It has multiple frontline clinical drugs with market advantages in China. At the same time, it focuses on tumors through independent development, external introduction, and project cooperation Develop innovative drugs and high-tech barrier generic drugs in the three core treatment fields of endocrine and autoimmune diseases. The company continues to carry out international product registration, international certification, consistency evaluation, and other work, and continues to achieve results. It has formed an international pharmaceutical industry system and maintains research and development and product cooperation relationships with multiple international innovative research and development enterprises. The pharmaceutical business of the company has four major business segments: Chinese and Western medicine, medical equipment, medicinal ginseng, and health industry, covering pharmaceutical wholesale, pharmaceutical retail, third-party pharmaceutical logistics with cold chain characteristics, pharmaceutical e-commerce, hospital value-added services, and the characteristic big health industry. It further expands the field of product agency and market expansion, and the traditional Chinese medicine industry constructs a complete industrial chain from base planting to decoction processing, automated decoction, and functional products, Provide comprehensive solutions for customers. The company's medical beauty business adheres to the strategy of "global operation layout and dual circulation business development". With an international perspective and forward-looking layout, it has more than 30 non-invasive and minimally invasive medical beauty products, including more than 20 products listed at home and abroad, and more than ten innovative products under research globally. The product portfolio covers non surgical mainstream medical beauty fields such as facial filling, facial cleaning, thread embedding, skin management, body shaping, hair removal, and private repair, A comprehensive product cluster has been formed, with the number and coverage of products ranking among the top in the industry. Sinclair, a wholly-owned subsidiary of the company, is a global medical beauty operation platform headquartered in the UK and has production bases in the Netherlands, France, the United States, Switzerland, and Bulgaria. Sinclair promotes and sells injectable long-acting microspheres, hyaluronic acid, and facial implants in the global market, and develops and expands its energy source medical beauty device business through wholly-owned subsidiaries HighTech and Viora in the global market. The medical beauty sector also includes the wholly-owned operating and sales subsidiary Xinkeli Aesthetics in the Chinese market, as well as the overseas technology research and development subsidiary R2 in the United States and Kylane in Switzerland. The company has been deeply involved in the field of industrial microbiology for over 40 years, with a solid industrial foundation and industrial transformation capabilities. It has successfully developed and manufactured various microbial drugs, and constructed a key technology system for microbial product research and production. The current scale and technical level of microbial fermentation products are at the leading level in the industry. We have three microbial research and development platforms in East China, Huida Biology, and Huiyi Biology, as well as five industrial bases in Hangzhou Xiangfuqiao, Qiantang New Area, Jiangsu Jiuyang, Meiqi Health, and Meihua High tech. We currently have the largest fermentation monomer workshop and industry-leading microbial drug production capacity in Zhejiang Province, covering various stages of microbial engineering technology such as strain construction, metabolic regulation, separation and purification, enzyme catalysis, and synthetic modification, A complete manufacturing system has been established for microbial project research and development, pilot testing, commercial production, engineering, and public system support. The company's comprehensive competitive strength, efficient operation, governance level, and value creation ability have been recognized by the market. It has been awarded Forbes' "Top 50 Best Listed Companies in the Asia Pacific", "Top 100 Value Listed Companies on the Chinese Main Board", and "Top 100 Golden Bull Listed Companies" multiple times, and has been listed on the Fortune China 500 for many consecutive years by Caifu Chinese website; In 2022, the company was selected into the "2021 China Pharmaceutical Industry Top 100" series of rankings on Mi Nei Net, ranking top 10 in a row; Awarded as one of the top 20 competitive pharmaceutical companies in China in 2022, as well as one of the "Top 500 Private Enterprises in China" and "Top 500 Service Industry Enterprises in China" by the China Enterprise Federation, and listed as one of the "Top 100 Enterprises in Zhejiang Province in 2022" and "Top 100 Service Industry Enterprises in Zhejiang Province in 2022". |
| Headquarter | Hangzhou |
| Establish Date | 3/31/1993 |
| Listed Code | 000963.SZ |
| Listed Date | 1/27/2000 |
| Chairman | Lv Liang. |
| CEO | Lv Liang. |
| Website | www.eastchinapharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
